-
-
公开(公告)号：KR100457790B1
公开(公告)日：2004-12-08
申请号：KR1020010047663
申请日：2001-08-08
Applicant: 충남대학교산학협력단
IPC: C12N15/86
Abstract: PURPOSE: Provided is a preparation of infectious HCV-like particles which are characteristically used as antigens for the detection HCV vaccine or HCV antibodies and for the inspection or examination of infection inhibiting drugs. CONSTITUTION: The preparation of infectious HCV-like particles is characterized by using a recombinant alphavirus expression vector(KCCM-10287) and a helper vector(KCCM-10286) which express HCV core, E1 and E2.
Abstract translation: 目的：提供一种感染性HCV样颗粒的制备物，其特征性地用作检测HCV疫苗或HCV抗体的抗原以及检测或检查感染抑制药物。 构成：通过使用表达HCV核心，E1和E2的重组α病毒表达载体（KCCM-10287）和辅助载体（KCCM-10286）来表征感染性HCV样颗粒的制备。
-
公开(公告)号：KR1020020067833A
公开(公告)日：2002-08-24
申请号：KR1020010008201
申请日：2001-02-19
Applicant: 충남대학교산학협력단
IPC: C12N15/86
CPC classification number: C12N15/86 , C07K14/4703 , C07K14/4746 , C12N5/0693
Abstract: PURPOSE: An Alphavirus expression vector capable of expressing a cancer-inhibiting protein, its producing method and its use are provided, thereby effectively inhibiting and preventing the growth of a cancer cell. CONSTITUTION: The Alphavirus expression vector capable of expressing a cancer-inhibiting protein contains a first cancer-inhibiting gene which is operably linked under operation of a first subgenomic promoter, a second cancer-inhibiting gene which is operably linked under operation of a second subgenomic promoter, and a third cancer-inhibiting gene which is operably linked under operation of a third subgenomic promoter, in which the cancer-inhibiting gene is selected from pRb/p110 or its homologue p107 and p120, p53 protein, p21 protein, p21 protein(WAF-1), bak, BRCA1, BRCA2, PTEN, APC, DCC, NF-1, NF-2, WT-1, MEN-I, MEN-II, zac1, p73, VHL, FCC and MCC; and the Alphavirus is Sindbis virus or Semliki Forest virus(SFV).
Abstract translation: 目的：提供能够表达癌抑制蛋白的甲病毒表达载体及其制备方法及其用途，从而有效抑制和预防癌细胞的生长。 构成：能够表达癌症抑制蛋白的甲病毒载体表达载体含有第一癌抑制基因，其在第一亚基因组启动子的操作下可操作地连接，第二癌抑制基因在第二亚基因组启动子的操作下可操作地连接 ，以及第三癌抑制基因，其在第三亚基因组启动子的操作下可操作地连接，其中所述癌抑制基因选自pRb / p110或其同源物p107和p120，p53蛋白，p21蛋白，p21蛋白（WAF -1），bak，BRCA1，BRCA2，PTEN，APC，DCC，NF-1，NF-2，WT-1，MEN-1，MEN-II，zac1，p73，VHL，FCC和MCC; 甲病毒属于辛德毕斯病毒或辛格利奇森林病毒（SFV）。
-
公开(公告)号：KR1020020060100A
公开(公告)日：2002-07-16
申请号：KR1020020001823
申请日：2002-01-08
Applicant: 충남대학교산학협력단
IPC: C12N15/86
CPC classification number: C12N15/86 , C12N5/0686 , C12N2740/16023 , C12N2740/16051 , C12N2770/36141 , G01N33/536 , G01N33/56988 , G01N33/6854 , G01N2333/16
Abstract: PURPOSE: Provided is HIV like particle which is composed of HIV-1 Gag, Env, Pol and/or Pro proteins expressed by an expression vector containing HIV-1 env, gag, pro, pol genes. The HIV like particle can be used as an antigen in a diagnosis kit of HIV infection and for HIV vaccine composition. CONSTITUTION: Alphavirus based expression vectors contain HIV-1 env, gag, pro and pol genes and they are as follows: pSFV/env-gag, pSFV/gag-env, pSFV/env-gag-pro, pSFV/env-gag-gagpro, pSFV/env-gag-gagΔpro, and pSFV/gagpol-env. The expression vectors further contains CTE(constitutive transport element) gene and they are as follows: pSFV/env-gag-gagpro-CTE, pSFV/env-gag-gagΔpro-CTE, pSFV/gagpol-env-MCTE, and pSF/gag-env-MCTE. HIV-like particle is manufactured by introducing one of the above vectors or its RNA transcript into an animal cell then expressing it.
Abstract translation: 目的：提供由含有HIV-1 env，gag，pro，pol基因的表达载体表达的由HIV-1Gag，Env，Pol和/或Pro蛋白组成的HIV样颗粒。 HIV样颗粒可用作HIV感染和HIV疫苗组成的诊断试剂盒中的抗原。 构成：基于甲病毒基因的表达载体含有HIV-1 env，gag，pro和pol基因，它们如下：pSFV / env-gag，pSFV / gag-env，pSFV / env-gag-pro，pSFV / env-gag- gagpro，pSFV / env-gag-gagΔpro和pSFV / gagpol-env。 表达载体还含有CTE（组成型转运元件）基因，它们如下：pSFV / env-gag-gagpro-CTE，pSFV / env-gag-gagΔpro-CTE，pSFV / gagpol-env-MCTE和pSF / gag -env-MCTE。 通过将上述载体之一或其RNA转录物引入动物细胞中然后进行表达来制备HIV样颗粒。
-
公开(公告)号：KR101919002B1
公开(公告)日：2018-11-20
申请号：KR1020160164441
申请日：2016-12-05
Applicant: 대한민국(농림축산식품부 농림축산검역본부장) , 충남대학교산학협력단
IPC: C07K14/005 , C12N15/70 , A61K39/135
Abstract: 본발명은혈청형이서로다른구제역바이러스의 VP1 단백질내 주요항원성에피토프들을코돈최적화하여연결한후 특이미생물발현시스템을이용하여융합단백질항원 (Multi-VP1 epitopes)을가용성의단백질 (Soluble protein)로발현시키는벡터, 이에의해형질전환된 미생물, 상기미생물로부터발현·정제된가용성 Multi-VP1 epitope 단백질및 상기단백질의백신목적으로의이용에대한것으로, 더욱자세하게는대장균의코돈에최적화되게유전자서열을변환한 O, A, Asia1 type 구제역바이러스혹은각각의동일혈청형내 서로다른지역형구제역바이러스의 VP1 단백질내 주요항원에피토프들을연결한유전자를포함하는대장균발현벡터, 상기의벡터로형질전환된 특이재조합대장균및, 상기의대장균으로부터발현및 정제된가용성의 Multi-VP1 epitope 단백질을유효성분으로하는구제역바이러스감염예방을위한백신에관한것이다.
-
Patent Agency Ranking
公开(公告)号：KR20180064158A
公开(公告)日：2018-06-14
申请号：KR20160164441
申请日：2016-12-05
Applicant: 대한민국(농림축산식품부 농림축산검역본부장) , 충남대학교산학협력단
IPC: C07K14/005 , A61K39/135 , C12N15/70
Abstract: 본발명은혈청형이서로다른구제역바이러스의 VP1 단백질내 주요항원성에피토프들을코돈최적화하여연결한후 특이미생물발현시스템을이용하여융합단백질항원 (Multi-VP1 epitopes)을가용성의단백질 (Soluble protein)로발현시키는벡터, 이에의해형질전환된 미생물, 상기미생물로부터발현·정제된가용성 Multi-VP1 epitope 단백질및 상기단백질의백신목적으로의이용에대한것으로, 더욱자세하게는대장균의코돈에최적화되게유전자서열을변환한 O, A, Asia1 type 구제역바이러스혹은각각의동일혈청형내 서로다른지역형구제역바이러스의 VP1 단백질내 주요항원에피토프들을연결한유전자를포함하는대장균발현벡터, 상기의벡터로형질전환된 특이재조합대장균및, 상기의대장균으로부터발현및 정제된가용성의 Multi-VP1 epitope 단백질을유효성분으로하는구제역바이러스감염예방을위한백신에관한것이다.
-
公开(公告)号：KR20180046968A
公开(公告)日：2018-05-10
申请号：KR20160142093
申请日：2016-10-28
Applicant: 성신여자대학교 산학협력단 , 충남대학교산학협력단 , 충북대학교 산학협력단
IPC: C07K14/005 , A61K39/145
CPC classification number: C07K14/005 , A61K39/145 , C12N2760/16123 , C12N2760/16134 , C12N2760/16151
Abstract: H5N8으로부터유래한헤마글루티닌(HA) 단백질및 뉴라미니다제(NA) 단백질를포함하고, H1N1으로부터유래한 M1 단백질을포함하는바이러스유사입자백신이개시된다. 상기바이러스유사입자백신은근육주사뿐만이아니라호흡주사를통해서도면역반응을유도할수 있다.
-
18.发明公开Ｌ형 폴리감마글루탐산을 생산하는 신규 미생물 바실러스 메가테리움 토하 및 이로부터 생산된 Ｌ형 폴리감마글루탐산 有权新型微生物生产L型聚氨基葡糖酸和L型聚氨基葡萄糖酸的新型微生物MOHATERIUM TOHA
公开(公告)号：KR1020120063025A
公开(公告)日：2012-06-15
申请号：KR1020100124020
申请日：2010-12-07
Applicant: 주식회사 바이오리더스 , 국민대학교산학협력단 , 한국생명공학연구원 , 충남대학교산학협력단
CPC classification number: C12R1/11 , A23L33/135 , A23L33/175 , A61K8/88 , A61K38/02 , A61K2800/10 , A61Q19/00 , C12N1/20 , C12P21/02
Abstract: PURPOSE: A novel microorganism which produces L-type poly gamma glutamic acid is provided to obtain the poly gamma glutamic acid used as a thickening agent, and biodegradable plastic solvent. CONSTITUTION: A novel microorganism, Bacillus megaterium Toha(KCTC 11752BP), produces L-type poly gamma glutamic acid. The strain is derived from a fermented food. The strain has 16S rDNA sequence of sequence number 1 and produces the poly gamma glutamic acid at low salinity. A probiotic composition contains Bacillus megaterium Toha (KCTC 11752BP) and the poly gamma glutamic acid.
Abstract translation: 目的：提供一种产生L-型polyγ谷氨酸的新型微生物，以获得用作增稠剂的聚γ谷氨酸和可生物降解的塑料溶剂。 构成：一种新型微生物，巨大芽孢杆菌Toha（KCTC 11752BP）产生L-型polyγ谷氨酸。 该菌株来自发酵食物。 该菌株具有序列号1的16S rDNA序列，并产生低盐度的多聚谷氨酸。 益生菌组合物含有巨大芽孢杆菌Toha（KCTC 11752BP）和聚γ谷氨酸。
-
19.发明授权
公开(公告)号：KR100857861B1
公开(公告)日：2008-09-11
申请号：KR1020070103512
申请日：2007-10-15
Applicant: 주식회사 바이오리더스 , 한국생명공학연구원 , 충남대학교산학협력단
CPC classification number: C07K14/475
Abstract: A surface expression vector for fusion protein of Myo-2 peptide multimer and myostatin is provided to express the myostatin fusion protein on the surface of bacteria, and increase the blood antibody production, body weight and muscle amount of animals by orally administering the bacteria. A myostatin derived peptide Myo-2 has the amino acid sequence of SEQ ID NO:1. A Myo-2 peptide multimer is prepared by polymerizing 2-8 Myo-2 peptides. A fusion protein is prepared by fusing the Myo-2 peptide multimer with matured myostatin. A surface expression vector for fusion protein contains a gene encoding polygammaglutamic acid synthetase complex selected from pgsB(polygammaglutamic acid synthetase), pgsC and pgsA, the nucleotide sequence encoding the Myo-2 peptide multimer and a gene encoding the matured myostatin. A method for producing a fusion protein-surface expressed microorganism comprises the steps of: (a) expressing the fusion protein of myostatin derived peptide multimer and matured myostatin on the surface of microorganism by culturing a microorganism transformed with the surface expression vector; and (b) recovering the microorganism with surface expressed matured myostatin, wherein the microorganism is lactic acid bacterium. Further, the matured myostatin is be derived from mammal or birds.
Abstract translation: 提供Myo-2肽多聚体和肌生成抑制素融合蛋白的表达表达载体，以表达细菌表面的肌生成抑制素融合蛋白，并通过口服施用细菌增加动物的血液抗体产生，体重和肌肉量。 肌生长抑制素衍生肽Myo-2具有SEQ ID NO：1的氨基酸序列。 通过聚合2-8个Myo-2肽制备Myo-2肽多聚体。 通过将Myo-2肽多聚体与成熟的肌生成抑制素融合来制备融合蛋白。 用于融合蛋白的表面表达载体包含编码聚腺苷酸合成酶复合物的基因，其选自pgsB（polygammaglutamic acid synthetase），pgsC和pgsA，编码Myo-2肽多聚体的核苷酸序列和编码成熟肌肉生长抑制素的基因。 一种融合蛋白表面表达微生物的制备方法，包括以下步骤：（a）通过培养用表面表达载体转化的微生物，将肌生长抑制素衍生肽多聚体和成熟肌生成抑制素的融合蛋白表达在微生物表面上; 和（b）用表面表达成熟的肌生长抑制素回收微生物，其中微生物是乳酸菌。 此外，成熟的肌生成抑制素来源于哺乳动物或鸟类。
-
公开(公告)号：KR100457791B1
公开(公告)日：2004-11-18
申请号：KR1020010008201
申请日：2001-02-19
Applicant: 충남대학교산학협력단
IPC: C12N15/86
Abstract: PURPOSE: An Alphavirus expression vector capable of expressing a cancer-inhibiting protein, its producing method and its use are provided, thereby effectively inhibiting and preventing the growth of a cancer cell. CONSTITUTION: The Alphavirus expression vector capable of expressing a cancer-inhibiting protein contains a first cancer-inhibiting gene which is operably linked under operation of a first subgenomic promoter, a second cancer-inhibiting gene which is operably linked under operation of a second subgenomic promoter, and a third cancer-inhibiting gene which is operably linked under operation of a third subgenomic promoter, in which the cancer-inhibiting gene is selected from pRb/p110 or its homologue p107 and p120, p53 protein, p21 protein, p21 protein(WAF-1), bak, BRCA1, BRCA2, PTEN, APC, DCC, NF-1, NF-2, WT-1, MEN-I, MEN-II, zac1, p73, VHL, FCC and MCC; and the Alphavirus is Sindbis virus or Semliki Forest virus(SFV).
Abstract translation: 目的：提供一种能够表达癌症抑制蛋白的甲病毒表达载体，其生产方法及其用途，由此有效地抑制和预防癌细胞的生长。 构成：能够表达癌症抑制蛋白的甲病毒表达载体含有第一种癌症抑制基因，该基因在第一亚基因组启动子的操作下可操作地连接，第二癌基因是在第二亚基因组启动子操作下可操作地连接的 和在第三亚基因组启动子的操作下可操作连接的第三癌抑制基因，其中所述癌抑制基因选自pRb / p110或其同源物p107和p120，p53蛋白，p21蛋白，p21蛋白（WAF -1），bak，BRCA1，BRCA2，PTEN，APC，DCC，NF-1，NF-2，WT-1，MEN-1，MEN-II，zac1，p73，VHL，FCC和MCC; 而α病毒是辛德毕斯病毒或塞姆利基森林病毒（SFV）。
-
-
-
-
-
-
-
-
-
Search Results
30
records
(took 0.026 seconds)
